03/14/2026
📣WANP 2026 Annual Conference | Speaker Highlight📣
Have you been prescribing GLP-1 agonists in your practice? Have you noticed benefits extending beyond glucose control and weight management? Have you been hearing about "microdosing" GLP-1s and been curious about this strategy?
If you answered "yes" to any of those questions, you should definitely come to our conference and learn from Dr. Jennifer Bennett about the emerging data behind these medications in the presentation *GLP-1 Agonists in Autoimmunity: How these diabetes medications are improving inflammation*.
*****
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), originally developed for type 2 diabetes and obesity, are increasingly recognized for their immunomodulatory and anti-inflammatory properties in autoimmune diseases, including rheumatoid arthritis, psoriatic arthritis, and systemic lupus erythematosus. Preclinical and clinical studies demonstrate that GLP-1 RAs can attenuate inflammatory cytokine expression, modulate innate and adaptive immune responses, and improve metabolic parameters, with some evidence of direct disease-modifying effects in inflammatory arthritis. Compared to traditional biologic therapies, GLP-1 RAs offer potential advantages in managing metabolic comorbidities and may serve as adjuncts or alternatives to biologics in certain populations.
*****
If you've attended prior conferences, you likely know that Dr. Bennett's presentations are interesting, informative, engaging, and fun - while focusing on research and clinical functionality of whatever it is she is presenting on. You won't regret learning from her!
Register today: wanp.org/2026conference